hit counter
BioCryst Pharmaceuticals, Inc. (BCRX) Stock News Sentiment & Price - Sentifly
BCRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BioCryst Pharmaceuticals, Inc. (BCRX)

USA
Biotechnology
NASDAQ
BCRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BCRX Latest news
GlobeNewsWire
Neutral
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2021-10-26 07:00

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place in New Orleans, Louisiana, and online, from November 4-8, 2021.

GlobeNewsWire
Neutral
BioCryst to Report Third Quarter 2021 Financial Results on November 3
2021-10-20 07:00

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

InvestorPlace
Positive
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
2021-10-18 13:42

These growth stocks could become multi-baggers in the future. Investors should consider them as they start to move at an aggressive pace.

The Motley Fool
Positive
2 Super-Charged Growth Stocks to Buy Now
2021-10-13 10:00

These two small drugmakers are poised for a long-winded growth spurt.

GlobeNewsWire
Neutral
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-04 07:00

RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 178,500 shares of BioCryst common stock on September 30, 2021 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The Motley Fool
Positive
3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
2021-09-30 06:17

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

GlobeNewsWire
Neutral
BioCryst to Present at 2021 Cantor Virtual Healthcare Conference
2021-09-21 07:00

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.

Benzinga
Positive
NICE Recommends BioCryst's Hereditary Angioedema Med
2021-09-16 11:50

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recommendation covers eligible patients 12 years and older if they have at least two attacks per month.

GlobeNewsWire
Neutral
NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
2021-09-15 20:20

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's (UK) National Institute for Health and Care Excellence (NICE) has recommended ORLADEYO® (berotralstat) for preventing recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older if they have at least two attacks per month. With this recommendation, HAE patients in England, Wales and Northern Ireland will have access to the first oral, once-daily therapy for routine prevention of recurrent HAE attacks.

Seeking Alpha
Neutral
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
2021-09-13 05:05

For the three months ended June 30, 2021, total revenues were $50.0 million compared to $2.9 million in the second quarter of 2020.

Loading more news...